PIPELINE

SC-1012 is a novel small molecule targeting an under-explored pathway for obesity and related metabolic disorders. Several genes with established metabolic relevance signal through this pathway, and emerging evidence supports it as a potential central metabolic control node.

This represents a first-in-class oral small molecule that provides weight loss equivalent to GLP-1 RAs and improved body composition showing enhanced fat loss and muscle preservation compared to semaglutide in animal models of obesity.

SC-2004 is our lead oral GLP-1R agonist, developed using our proprietary method of fine-tuned receptor modulation.

Treated animals have shown comparable weight loss to GLP-1 peptides with normalization of hyperglycemia.

These molecules represent our efforts to develop a widely available, easily manufactured oral therapeutics to provide obesity treatments with enhanced tolerability, body composition, safety, convenience, and broad efficacy.